Biologic medications that provide blockade of interleukin-1 (Il-1) and interleukin-6 (Il-6) appear to be most effective current treatment of children with SoJIA in 2014. The gene discussed is IL1B; the disease is systemic-onset juvenile idiopathic arthritis.